PATENT CLAIM ANALYSIS

Application Number: 15879130
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["548", "309700"]

Abstract:
The present invention is directed to bendamustine esters and bendamustine amides and their use for the treatment of cancer.

Claim (Index 2):
A method of treating cancer in a patient, the method comprising administering to said patient a pharmaceutical composition, wherein said pharmaceutical composition comprises:\n (a) a compound of formula (II) wherein R 2  is C 1 -C 24 alkylene and R 3  is \u2014COOC 1-3 alkyl; or R 2 -R 3  is C 8 C 24 alkyl, or a pharmaceutically acceptable salt thereof; and\n (b) a means for increasing the circulation time of the compound of formula (II), or a pharmaceutically acceptable salt thereof, in an aqueous environment.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 86.0
- Lexical Diversity: 1.11111
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15456439', '14442088', '15184968', '14711747', '14699965']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7708884815811983
- 35 USC 102 Novelty (BERT): 0.5381732923079773
- Combined Prediction Score: 0.7476169626538762
- Mean Citation Score: 360.282652
- Max Citation Score: 380.62274
- Similarity Product: 347.80795569886567

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test